China-based Shunxi Holding Group Co. Ltd has entered into a licensing deal with Australia-based firm Cartherics Pty Ltd, securing the exclusive rights to develop, manufacture, and commercialize Cartherics’ autologous CAR-T cell product, CTH-004, for the treatment of multiple solid tumors, including ovarian cancer, in Greater China. The agreement also grants Shunxi the option to negotiate rights to other CAR-T products that incorporate the licensed intellectual property (IP), with financial terms including a license fee, milestone payments, and royalties remaining undisclosed.
Promising Results and Upcoming Clinical Trial for CTH-004
CTH-004 has demonstrated promising results in animal models of ovarian cancer and is slated for evaluation in an upcoming clinical trial. This trial will be conducted under a research and development collaboration with the Peter MacCallum Cancer Centre, as announced earlier this year, marking a significant step towards potential clinical applications of this therapy.
Cartherics’ Patent Strengthens Position in the Chinese Market
Cartherics was granted a Chinese patent ZL 201680069543.6 in January of this year, titled “Genetically modified cells and uses thereof”. This patent bolsters Cartherics’ proprietary position for multiple development candidates within its pipeline, specifically covering Cartherics’ chimeric antigen receptor (CAR) targeting tumor-associated glycoprotein-72 (TAG-72), along with T cells bearing the TAG-T cell receptor. This intellectual property protection is crucial for the company’s competitive edge and potential market exclusivity in China.-Fineline Info & Tech
